Avadel Pharmaceuticals plc [NASDAQ: AVDL] stock went on a downward path that fall over -10.62% on Wednesday, amounting to a one-week price decrease of less than -11.25%.
Over the last 12 months, AVDL stock rose by 9.50%. The one-year Avadel Pharmaceuticals plc stock forecast points to a potential upside of 29.65. The average equity rating for AVDL stock is currently 1.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $1.54 billion, with 89.83 million shares outstanding and 85.14 million shares in the current float. Compared to the average trading volume of 1.20M shares, AVDL stock reached a trading volume of 4207332 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Avadel Pharmaceuticals plc [AVDL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AVDL shares is $23.10 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AVDL stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Avadel Pharmaceuticals plc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on March 05, 2024. While these analysts kept the previous recommendation, Needham raised their target price from $20 to $22. The new note on the price target was released on March 05, 2024, representing the official price target for Avadel Pharmaceuticals plc stock. Previously, the target price had yet another raise from $21 to $25, while H.C. Wainwright kept a Buy rating on AVDL stock.
The Average True Range (ATR) for Avadel Pharmaceuticals plc is set at 1.01, with the Price to Sales ratio for AVDL stock in the period of the last 12 months amounting to 28.00. The Price to Book ratio for the last quarter was 19.92, with the Price to Cash per share for the same quarter was set at 0.93.
AVDL Stock Performance Analysis:
Avadel Pharmaceuticals plc [AVDL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -11.25. With this latest performance, AVDL shares dropped by -3.10% in over the last four-week period, additionally plugging by 51.30% over the last 6 months – not to mention a rise of 9.50% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AVDL stock in for the last two-week period is set at 39.48, with the RSI for the last a single of trading hit 30.90, and the three-weeks RSI is set at 44.75 for Avadel Pharmaceuticals plc [AVDL]. The present Moving Average for the last 50 days of trading for this stock 16.69, while it was recorded at 18.03 for the last single week of trading, and 13.78 for the last 200 days.
Insight into Avadel Pharmaceuticals plc Fundamentals:
Avadel Pharmaceuticals plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.60 and a Current Ratio set at 2.85.
AVDL Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AVDL. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Avadel Pharmaceuticals plc go to 15.00%.
Avadel Pharmaceuticals plc [AVDL] Institutonal Ownership Details
The top three institutional holders of AVDL stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in AVDL stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in AVDL stock with ownership which is approximately 5.8386%.
